Sangamo Therapeutics Q3 revenue falls short, net loss widens

Reuters

2025/11/06

Sangamo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 revenue falls short, net loss widens

Overview

Sangamo Q3 2025 revenue misses analyst expectations, declining significantly from last year
Net loss for Q3 2025 was $34.9 mln, compared to net income last year
Company progresses Fabry disease program, preparing for BLA submission in 2026

Outlook

Sangamo expects BLA submission for Fabry disease in Q1 2026
Company plans CTA submission for prion disease by mid-2026
Sangamo reiterates 2025 operating expenses guidance of $135 mln to $155 mln

Result Drivers

NET LOSS - Consolidated net loss for the third quarter ended September 30, 2025 was $34.9 million, or $0.11 per share, compared to net income of $10.7 million, or $0.04 per share on a fully diluted basis, for the same period in 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Miss	$581,000	$34.40 mln (5 Analysts)
Q3 Net Income		-$34.93 mln
Q3 Adjusted Operating Expenses		$33 mln
Q3 Operating Expenses		$36.10 mln
Q3 Operating Income		-$35.55 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Sangamo Therapeutics Inc is $2.00, about 72.5% above its November 5 closing price of $0.55

Press Release: ID:nGNX7VN1Wp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581093096"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581093096\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581093096?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581093096","market":"us","top_or_hot":-1,"title":"Sangamo Therapeutics Q3 revenue falls short, net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sangamo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 revenue falls short, net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Sangamo Q3 2025 revenue misses analyst expectations, declining significantly from last year</p></li><li><p>Net loss for Q3 2025 was $34.9 mln, compared to net income last year</p></li><li><p>Company progresses Fabry disease program, preparing for BLA submission in 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Sangamo expects BLA submission for Fabry disease in Q1 2026</p></li><li><p>Company plans CTA submission for prion disease by mid-2026</p></li><li><p>Sangamo reiterates 2025 operating expenses guidance of $135 mln to $155 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NET LOSS - Consolidated net loss for the third quarter ended September 30, 2025 was $34.9 million, or $0.11 per share, compared to net income of $10.7 million, or $0.04 per share on a fully diluted basis, for the same period in 2024 </p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$581,000</p></td><td><p>$34.40 mln (5 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$34.93 mln</p></td><td></td></tr><tr><td><p>Q3 Adjusted Operating Expenses</p></td><td></td><td><p>$33 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$36.10 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$35.55 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/SGMO\">Sangamo Therapeutics Inc</a> is $2.00, about 72.5% above its November 5 closing price of $0.55</p></li></ul><p>Press Release: <span>ID:nGNX7VN1Wp</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sangamo Therapeutics Q3 revenue falls short, net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSangamo Therapeutics Q3 revenue falls short, net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 21:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sangamo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 revenue falls short, net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Sangamo Q3 2025 revenue misses analyst expectations, declining significantly from last year</p></li><li><p>Net loss for Q3 2025 was $34.9 mln, compared to net income last year</p></li><li><p>Company progresses Fabry disease program, preparing for BLA submission in 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Sangamo expects BLA submission for Fabry disease in Q1 2026</p></li><li><p>Company plans CTA submission for prion disease by mid-2026</p></li><li><p>Sangamo reiterates 2025 operating expenses guidance of $135 mln to $155 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NET LOSS - Consolidated net loss for the third quarter ended September 30, 2025 was $34.9 million, or $0.11 per share, compared to net income of $10.7 million, or $0.04 per share on a fully diluted basis, for the same period in 2024 </p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$581,000</p></td><td><p>$34.40 mln (5 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$34.93 mln</p></td><td></td></tr><tr><td><p>Q3 Adjusted Operating Expenses</p></td><td></td><td><p>$33 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$36.10 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$35.55 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/SGMO\">Sangamo Therapeutics Inc</a> is $2.00, about 72.5% above its November 5 closing price of $0.55</p></li></ul><p>Press Release: <span>ID:nGNX7VN1Wp</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGMO","symbol_name":"Sangamo Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0R0:1","article_id":"2581093096","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581093096","pubTimestamp":1762434750,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sangamo Therapeutics Q3 revenue falls short, net loss widensOverviewSangamo Q3 2025 revenue misses analyst expectations, declining significantly from last yearNet loss for Q3 2025 was $34.9 mln, compa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SGMO":"Sangamo Therapeutics Inc","BK4139":"生物科技","BK4556":"基因编辑"},"translate_title":"Sangamo Therapeutics第三季度收入不足，净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGMO":0.9},"content_text":"Sangamo Therapeutics Q3 revenue falls short, net loss widensOverviewSangamo Q3 2025 revenue misses analyst expectations, declining significantly from last yearNet loss for Q3 2025 was $34.9 mln, compared to net income last yearCompany progresses Fabry disease program, preparing for BLA submission in 2026OutlookSangamo expects BLA submission for Fabry disease in Q1 2026Company plans CTA submission for prion disease by mid-2026Sangamo reiterates 2025 operating expenses guidance of $135 mln to $155 mlnResult DriversNET LOSS - Consolidated net loss for the third quarter ended September 30, 2025 was $34.9 million, or $0.11 per share, compared to net income of $10.7 million, or $0.04 per share on a fully diluted basis, for the same period in 2024 Key DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueMiss$581,000$34.40 mln (5 Analysts)Q3 Net Income-$34.93 mlnQ3 Adjusted Operating Expenses$33 mlnQ3 Operating Expenses$36.10 mlnQ3 Operating Income-$35.55 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Sangamo Therapeutics Inc is $2.00, about 72.5% above its November 5 closing price of $0.55Press Release: ID:nGNX7VN1WpFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}